PriceTargets.com logo

Lipocine - LPCN Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $68.00
  • Forecasted Upside: 1,434.99%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$4.43 As of 06/8/2023 01:00 AM ET
▼ -0.03 (-0.67%)

This chart shows the closing price for LPCN by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Lipocine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LPCN and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LPCN

Analyst Price Target is $68.00
▲ +1,434.99% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Lipocine in the last 3 months. The average price target is $68.00, with a high forecast of $68.00 and a low forecast of $68.00. The average price target represents a 1,434.99% upside from the last price of $4.43.

This chart shows the closing price for LPCN for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Lipocine. This rating has held steady since August 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/15/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/10/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/8/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022LADENBURG THALM/SH SHBoost Target$68.00Low
8/26/2021HC WainwrightBoost TargetPositive ➝ Buy$42.50 ➝ $59.50High
6/24/2021Cantor FitzgeraldInitiated CoverageOverweight$51.00High
5/27/2021HC WainwrightLower TargetBuy$51.00 ➝ $42.50Low
1/19/2021HC WainwrightReiterated RatingBuy$51.00High
12/10/2020HC WainwrightReiterated RatingBuyMedium
12/10/2020LADENBURG THALM/SH SHUpgradeNeutral ➝ Buy$51.00High
5/27/2020HC WainwrightBoost TargetBuy$34.00 ➝ $51.00High
11/11/2019HC WainwrightLower TargetBuy ➝ Hold$85.00 ➝ $34.00Low
11/11/2019LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
5/15/2019HC WainwrightReiterated RatingBuy$85.00Low
3/11/2019HC WainwrightReiterated RatingBuy$51.00High
1/17/2019LADENBURG THALM/SH SHReiterated RatingBuyHigh
11/19/2018HC WainwrightSet TargetBuy$51.00Medium
(Data available from 6/8/2018 forward)

News Sentiment Rating

0.24 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/9/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/10/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/9/2023
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/9/2023
  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/8/2023

Current Sentiment

  • 1 very positive mentions
  • 12 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Lipocine logo
Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.
Read More

Today's Range

Now: $4.43
Low: $4.41
High: $4.70

50 Day Range

MA: $4.73
Low: $3.53
High: $5.47

52 Week Range

Now: $4.43
Low: $3.30
High: $15.64

Volume

5,188 shs

Average Volume

19,283 shs

Market Capitalization

$23.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Lipocine?

The following Wall Street research analysts have issued stock ratings on Lipocine in the last twelve months: LADENBURG THALM/SH SH, and StockNews.com.
View the latest analyst ratings for LPCN.

What is the current price target for Lipocine?

1 Wall Street analysts have set twelve-month price targets for Lipocine in the last year. Their average twelve-month price target is $68.00, suggesting a possible upside of 1,431.5%. LADENBURG THALM/SH SH has the highest price target set, predicting LPCN will reach $68.00 in the next twelve months. LADENBURG THALM/SH SH has the lowest price target set, forecasting a price of $68.00 for Lipocine in the next year.
View the latest price targets for LPCN.

What is the current consensus analyst rating for Lipocine?

Lipocine currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for LPCN.

What other companies compete with Lipocine?

Other companies that are similar to Lipocine include Acer Therapeutics, Unicycive Therapeutics, Cumberland Pharmaceuticals, AgeX Therapeutics and VBI Vaccines. Learn More about companies similar to Lipocine.

How do I contact Lipocine's investor relations team?

Lipocine's physical mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company's listed phone number is (801) 994-7383 and its investor relations email address is j[email protected]. The official website for Lipocine is www.lipocine.com. Learn More about contacing Lipocine investor relations.